Adding bile acid treatment to prevent C. diff from returning
Part of Infections clinical trials.
This study tests whether adding a common bile acid (ursodeoxycholic acid) to your regular C. diff treatment can help stop the infection from coming back. The goal is to see if this extra medicine reduces the chance of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have tested positive for a C. diff infection.
- You have at least one factor that raises your risk of the infection coming back (like being older, having been in the hospital, or taking antibiotics).
- You are currently taking or about to start a standard C. diff medicine (Flagyl, Vancomycin, or Dificid).
- You are expected to live at least 6 more months and do not have severe colitis or an intestinal blockage.
- You do not have severe liver disease, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether specific lifestyle changes during treatment for C. difficile infection (a serious gut bacteria infection) can help prevent it from coming back. You'll receive standard antibiotic treatment and follow a controlled diet while researchers track your recovery.
This study tests a new antibody (AZD5148) to prevent C. diff infection from coming back. If you have a current C. diff infection and are being treated with antibiotics, you may be able to join.
This trial compares three treatments for a severe diarrhea infection called C. diff: a fecal transplant (putting healthy donor stool into your gut), a newer antibiotic called fidaxomicin, and an older antibiotic called vancomycin. The goal is to see which works best and prevents the infection from coming back.
This study tests whether the supplement alanyl-glutamine, given along with standard treatment, can improve outcomes for adults being treated for C. difficile infection (a cause of diarrhea). It may help the body recover better after antibiotics that usually treat C. difficile.
This study tests a new live bacteria product (EXL01) given with vancomycin to prevent C. diff from coming back. It is for people who have already had C. diff two or more times and are at high risk of another infection.
This trial tests a new medicine called VE303, a live bacterial therapy, to prevent C. diff infections from coming back. It is for people who have had C. diff at least once in the last 6 months, or who are at high risk for a repeat infection due to age or other health problems.
Hear when a new Clostridioides Difficile Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.